Opthea (ASX/NASDAQ:OPT) announced the appointment of Kathy Connell to its board of directors as a non-executive director.
Ms. Connell brings extensive business development expertise across pharmaceutical, vaccine, medtech, consumer, and digital health industries, with a proven track record of translating global commercial strategies into impactful business outcomes and shareholder value.
“We are pleased to welcome Kathy Connell to Opthea’s BOD,” said Jeremy Levin, D.Phil., chairman of the board of Opthea.
“Her wealth of experience in driving strategic growth and business success in the global healthcare industry will be an invaluable asset as the company prepares for the sozinibercept Phase 3 data readout and subsequent regulatory and commercial milestones. We believe sozinibercept could represent a medical breakthrough for the treatment of wet AMD,” Dr. Levin added.
